Febrile neutropenia (FN) is among the most common complications of chemotherapy, and a recent post-marketing, multi-center, real-world, non-interventional, epidemiological study sought to examine the use, safety, and efficacy of biosimilar filgrastim in the primary and secondary prevention of FN.
Febrile neutropenia (FN) is among the most common complications of chemotherapy, and a recent post-marketing, multi-center, real-world, non-interventional, epidemiological study sought to examine the use, safety, and efficacy of biosimilar filgrastim in the primary and secondary prevention of FN.
Secondary prevention of FN is typically offered to a patient who is in a low-risk category for developing FN, but who develops FN during chemotherapy. Primary prevention of FN is offered to high-risk patients with each cycle of chemotherapy. Of the 170 study participants, an overall risk assessment conducted at the first patient visit resulted in the following determinations:
After the risk assessment, 60% of patients received biosimilar filgrastim (Accofil, manufactured by Accord Healthcare, who sponsored the study) as primary prevention of FN, and 40% received biosimilar treatment as secondary prevention. During the second to fifth patient visit (though in 40.6% of patients, 6 cycles of chemotherapy were planned, and in 28.2% of cases, more than 6 cycles were planned), the course of therapy with biosimilar filgrastim was monitored. Data collected, via questionnaire, included the following:
The researchers calculated continuation of therapy with biosimilar filgrastim, average dose of filgrastim, chemotherapy dosage, and FN at each of the 5 visits, and found the following:
An assessment of patient reports found that 70% of patients self-administered the filgrastim injection, and at each visit, over 50% of patients reported “little” soreness caused by the injection. Patient assessments of the convenience of use (on a scale of 1 to 10, where 1 is the least convenient and 10 is the most convenient), showed that approximately 50% of patients rated the convenience of administration as greater than 8.
Assessment of hematological parameters showed that the median neutrophil count identified at visit 1 (2.2×103/µl) did not fall during any of the 5 visits.
The researchers concluded that biosimilar filgrastim was safe, effective, and well tolerated in patients in the primary and secondary prevention of chemotherapy-induced FN, and that administration of the drug was convenient for, and well accepted by, patients.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.